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Summary
 
Infiltrating leukocytes may be responsible for autoimmune disease. We hypothesized that the
chemokine monocyte chemoattractant protein (MCP)-1 recruits macrophages and T cells into
 
tissues that, in turn, are required for autoimmune disease. Using the MRL-
 
Fas
 
lpr
 
 strain with
spontaneous, fatal autoimmune disease, we constructed MCP-1–deficient MRL-
 
Fas
 
lpr
 
 mice. In
MCP-1–intact MRL-
 
Fas
 
lpr
 
 
 
mice, macrophages and T cells accumulate at sites (kidney tubules,
glomeruli, pulmonary bronchioli, lymph nodes) in proportion to MCP-1 expression. Deleting
MCP-1 dramatically reduces macrophage and T cell recruitment but not proliferation, protects
from kidney, lung, skin, and lymph node pathology, reduces proteinuria, and prolongs survival.
Notably, serum immunoglobulin (Ig) isotypes and kidney Ig/C3 deposits are not diminished in
MCP-1–deficient MRL-
 
Fas
 
lpr
 
 mice, highlighting the requirement for MCP-1–dependent leu-
kocyte recruitment to initiate autoimmune disease. However, MCP-1–deficient mice are not
completely protected from leukocytic invasion. T cells surrounding vessels with meager MCP-1
expression remain. In addition, downstream effector cytokines/chemokines are decreased in
MCP-1–deficient mice, perhaps reflecting a reduction of cytokine-expressing leukocytes.
Thus, MCP-1 promotes MRL-
 
Fas
 
lpr
 
 autoimmune disease through macrophage and T cell re-
cruitment, amplified by increasing local cytokines/chemokines. We suggest that MCP-1 is a
principal therapeutic target with which to combat autoimmune diseases.
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I
 
nfiltrating mononuclear leukocytes may be responsible for
autoimmune tissue injury (1, 2). The migration of leuko-
cytes through vessels and beyond the vascular compartment
is dependent in part on small chemoattractant proteins
called chemokines. Within the chemokine family, a series
of reports suggest that monocyte chemoattractant protein
(MCP)-1
 
1
 
 may be responsible for inflammation in tissues
during autoimmune disease. This is based on (a) MCP-1 tis-
sue expression in human systemic lupus erythematosus, rheu-
matoid arthritis (3–5), and experimental mouse models of
lupus (NZB/W mice) and allergic encephalomyelitis (6–7);
(b) MCP-1 chemoattraction for monocytes and memory T
cells (8–10); and (c) MCP-1 regulation of leukocyte func-
tion via modulation of adhesion molecule expression and T
cell activation and proliferation (11–14). Thus, MCP-1 may
be the principal chemokine responsible for initiating autoim-
mune tissue damage.
Strategies that neutralize or eliminate MCP-1 are protec-
tive in induced models of inflammation (15–19). MCP-1
antibody neutralization markedly reduces infiltrating macro-
phages and T cells in induced models of kidney and lung
injury (16–19). However, antibody-based therapies have
limitations; they do not necessarily deplete the target mole-
cule and may even initiate harmful immune reactions. Per-
haps the most convincing evidence supporting the require-
ment for MCP-1 in inflammation is illustrated in MCP-1
gene–disrupted mice. For example, MCP-1–deficient mice
mount meager responses to inflammatory or immune stim-
ulants, as evidenced in thioglycolate-elicited peritonitis, de-
layed-type hypersensitivity responses, and pulmonary gran-
ulomas (20). Furthermore, using a form of rapidly progressive
kidney disease responsible for tubular and glomerular in-
jury, nephrotoxic serum nephritis (NSN), we established
that MCP-1–deficient B6/129 mice are spared from tubu-
lar but not glomerular destruction (21). This structure-spe-
 
1
 
Abbreviations used in this paper:
 
 gcs, glomerular cross sections; MCP,
monocyte chemoattractant protein; NSN, nephrotoxic serum nephritis;
PAS, periodic acid Schiffs; PCNA, proliferating cell nuclear antigen;
TECs, tubular epithelial cells. 
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cific protection is based on the abundant expression of
MCP-1 in tubular epithelial cells (TECs) and nominal ex-
pression in glomeruli. However, the rapid pace of tissue
destruction in NSN has made it difficult to identify specific
molecular mechanisms of disease and is not representative
of most human kidney diseases.
It is unclear whether blocking MCP-1 is a beneficial ther-
apeutic strategy for human autoimmune diseases. MCP-1 is a
member of a large family of leukocyte chemokines, and sev-
eral of these chemokines are coexpressed in tissues during
inflammation (22). Thus, the possibility of MCP-1 as a
therapeutic target is dependent upon its relative importance
among the chemokines, cytokines, and other molecules that
are expressed during progressive tissue destruction. The
challenge remains to determine whether the genetic dele-
tion of MCP-1 prevents disease in progressive human ill-
nesses and to decipher the mechanism responsible for
MCP-1–mediated injury.
The MRL-
 
Fas
 
lpr
 
 mouse strain is particularly valuable to
understanding the pathogenesis of autoimmune disease, as
tissue destruction in this model is spontaneous, predictable,
steadily progressive, fatal, and shares features with human
systemic lupus erythematosus (23). Furthermore, the tempo
of disease is sufficiently long to tease apart pathogenesis but
short enough to be economically feasible for experimental
studies. The phenotypic expression of autoimmune disease
in MRL-
 
Fas
 
lpr
 
 
 
mice is characterized by a large tissue infil-
tration of mononuclear leukocytes that is responsible for
lymphadenopathy, splenomegaly, and autoimmune injury
in multiple tissues, including the kidney, lung, and skin
(23). Kidney disease in MRL-
 
Fas
 
lpr
 
 
 
mice is fatal and com-
plex and consists of glomerular, tubular/interstitial, and
vascular components mediated by infiltrating macrophages
and T cells. Furthermore, the pathogenic events in each
component within the kidney are distinctive. We reason
that chemokines that recruit mononuclear leukocytes into the
kidney and other tissues targeted for autoimmune disease
are responsible for eliciting this cascade of events culminat-
ing in fatal autoimmune disease. Therefore, we hypothe-
size that MCP-1 is responsible for recruiting macrophages
and T cells and thereby initiating disease in the kidney and
other tissues undergoing autoimmune disease in MRL-
 
Fas
 
lpr
 
 mice. To test this hypothesis, we have constructed an
MCP-1–deficient MRL-
 
Fas
 
lpr
 
 
 
strain, evaluated pathology
(kidney, lung, skin, lymph nodes, and spleen) and survival,
and determined the mechanism responsible for leukocytic
accumulation within these tissues.
 
Materials and Methods
 
Mice.
 
MRL/MpJ
 
11
 
 (MRL
 
11
 
), MRL/MpJ-
 
Fas
 
lpr
 
/Fas
 
lpr
 
 (MRL-
 
Fas
 
lpr
 
), C3H/FeJ, and C57BL/6 mice were purchased from the
The Jackson Laboratory. MCP-1–intact and –deficient B6/129
mice (129SV/J 
 
3
 
 C57BL/6)F
 
1
 
 were constructed as described
(20). Control MCP-1–intact B6/129 mice were derived from
matings of mice heterozygous for the disrupted allele. All mice
were maintained in a pathogen-free animal facility.
 
Generating MCP-1–deficient MRL-Fas
 
lpr
 
 Mice.
 
MCP-1–deficient
 
(MCP-1
 
2
 
/
 
2
 
) MRL
 
-Fas
 
lpr
 
 mice were created by a series of genetic
backcrosses using the cross-backcross-intercross scheme. MRL-
 
Fas
 
lpr
 
 
 
mice were mated with MCP-1
 
2
 
/
 
2
 
 (129/Sv 
 
3
 
 C57BL/6)
mice to yield heterozygous F1 offspring. We intercrossed F1
mice and screened the progeny by PCR amplification of tail ge-
nomic DNA for the 
 
Fas
 
lpr
 
 
 
mutation and MCP-1 using specific
primers (21, 24). Double homozygotes (
 
Fas
 
lpr
 
/Fas
 
lpr
 
MCP-1
 
2
 
/
 
2
 
)
N1F1 progeny were backcrossed to MRL-
 
Fas
 
lpr 
 
mice. B1 prog-
eny, homozygous for the 
 
Fas
 
lpr
 
 
 
mutation and heterozygous for
MCP-1 (MCP-1
 
1
 
/
 
2
 
), were intercrossed, and mice homozygous
for the disrupted MCP-1 gene were selected by PCR typing for
continued backcrossing. After three generations of backcross–
intercross matings, this breeding scheme generated a colony of
MRL-
 
Fas
 
lpr
 
 
 
mice (94% MRL-
 
Fas
 
lpr
 
 background) homozygous
and heterozygous for the disrupted MCP-1 gene. We analyzed
the third generation, as we have previously established that there
are sufficient MRL
 
-Fas
 
lpr
 
 background genes to result in pheno-
typic changes characteristic of the wild-type MRL-
 
Fas
 
lpr
 
 
 
strain
(25). In addition, we compared sex-matched littermates to mini-
mize variability. The MCP-1
 
2
 
/
 
2
 
 MRL-
 
Fas
 
lpr
 
 mice are termed
MCP-1 deficient, whereas the MCP-1
 
1
 
/
 
1
 
MCP-1
 
1
 
/
 
2
 
 MRL-
 
Fas
 
lpr
 
mice are termed MCP-1–intact MRL-
 
Fas
 
lpr
 
 mice.
 
Proteinuria.
 
Urine protein levels in MCP-1–intact and –defi-
cient MRL-
 
Fas
 
lpr
 
 
 
mice were assessed semiquantitatively by dip-
stick analysis (Albustix; Bayer Diagnostic Division) on a monthly
basis beginning at 2 mo of age. On the day of analysis, dipstick
proteinuria measurements were taken from individual mice in the
morning and evening. If the measurements were inconsistent, the
animal was reassessed the following day.
 
Lymphadenopathy, Splenomegaly, and Skin Lesions.
 
Protruding
lymph nodes (cervical, brachial, and inguinal) and skin lesions
were assessed monthly beginning at 3 mo of age. Lymph node
score based on palpable nodes: 0
 
 5 
 
none; 1
 
 5 
 
small, at one site; 2
 
 5
 
moderate, at two different sites; and 3
 
 5 
 
large, at three or more
different sites. Skin lesion score by gross pathology: 0
 
 5 
 
none; 1
 
 5
 
small (face or ears); 2
 
 5 
 
moderate, 
 
,
 
2 cm (face, ears, and back);
and 3
 
 5 
 
severe, 
 
.
 
2 cm (face, ears, and back). Splenomegaly was
determined by spleen weights.
 
Renal Pathology.
 
Kidneys were fixed in 10% formalin for 24 h
at 4
 
8
 
C. Paraffin sections (4 
 
m
 
m) were stained with hematoxylin
and periodic acid Schiffs (PAS) reagent. We evaluated glomerular
pathology by assessing 50 glomerular cross sections (gcs) per kid-
ney and scored each glomerulus on a semiquantitative scale: 0
 
 5
 
normal (35–40 cells/gcs); 1
 
 5 
 
mild (glomeruli with few lesions
showing slight proliferative changes, mild hypercellularity [41–50
cells/gcs], and/or minor exudation); 2
 
 5 
 
moderate (glomeruli with
moderate hypercellularity [50–60 cells/gcs], including segmental
and/or diffuse proliferative changes, hyalinosis, and moderate ex-
udate); and 3
 
 5 
 
severe (glomeruli with segmental or global scle-
rosis and/or exhibiting severe hypercellularity [
 
.
 
60 cells/gcs],
necrosis, crescent formation, and heavy exudation). Damaged
tubules (percent; consisting of dilation and/or atrophy and/or
necrosis) were determined in 400 randomly selected renal cortical
tubules per kidney (
 
3
 
400). Perivascular cell accumulation was
determined semiquantitatively by scoring the number of cell lay-
ers surrounding the majority of vessel walls (score: 0
 
 5 
 
none; 1
 
 5
,
 
5; 2
 
 5 
 
5–10; and 3
 
 5 .
 
10). Scoring was evaluated using coded
slides.
 
Lung Pathology.
 
The lungs were inflated and fixed with 10%
formalin, and paraffin sections (4 
 
m
 
m) were stained with hematox-
ylin and PAS reagent. Perivascular and peribronchiolar infiltrates
were assessed semiquantitatively in 
 
.
 
20 vessels per section and in
 
.
 
20 bronchioli per section (number of cell layers surrounding 
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the majority of vessels or bronchioli: 0
 
 5 
 
none; 1
 
 5 
 
1–3; 2
 
 5 
 
3–6;
and 3
 
 5 .
 
6).
 
Antibodies.
 
The following primary antibodies were used for
immunostaining: rat anti–mouse CD4 IgG2a clone RM4-5
(PharMingen) to detect CD4 T cells; rat anti–mouse CD8a (Ly-2)
IgG2a clone 53-6.7 (PharMingen) to detect CD8 T cells; rat
anti–mouse CD45R/B220 IgG2a clone RA3-6B2 (PharMingen)
to detect CD4/CD8 T cells; rat anti–mouse CD21/35 IgG2b clone
7G6 (PharMingen) to detect B cells; rat anti–mouse monocyte/
macrophage IgG2b clone MOMA-2 (BioSource International)
and rat anti–mouse macrophage IgG2b (prepared from F4/80 hy-
bridoma supernatant; American Type Culture Collection num-
ber HB198) to detect macrophages; rabbit anti–mouse MCP-1
IgG (Serotec Ltd.) to detect MCP-1; mouse anticytokeratin
peptide 18 IgG1 clone CY-90 (Sigma Chemical Co.) to detect
epithelial cells; fluorescein-conjugated mouse anti-PCNA (prolif-
erating cell nuclear antigen) IgG1 clone 19F4 (Boehringer Mann-
heim) to detect proliferating cells; fluorescein-conjugated goat
anti–mouse IgG (Organon Teknika) to detect mouse IgG; and
fluorescein-conjugated goat anti–mouse C3 (Organon Teknika)
to detect mouse complement C3. The negative isotype control
antibodies for immunostaining were rat IgG2a clone R35-95, rat
IgG2b clone R35-38, mouse IgG1 clone MOPC-21 (PharMin-
gen), and normal rabbit IgG (Sigma Chemical Co.). The second-
ary antibodies for immunostaining were biotin-conjugated rabbit
anti–rat IgG and biotin-conjugated goat anti–rabbit IgG (Vector
Labs.). ELISA analysis of serum Ig (total Ig, IgM, IgG1, IgG2a,
IgG2b, and IgG3) was performed using isotype-specific standards,
goat anti–mouse capture antibodies, and alkaline phosphatase–
conjugated goat anti–mouse detection antibodies (Southern Bio-
technology Associates Inc.).
 
Identifying Infiltrating Cells.
 
To analyze kidney- and lung-
infiltrating T cells and interstitial macrophages, cryostat tissue
sections (4 
 
m
 
m) were fixed in ethanol at 4
 
8
 
C for 10 min and im-
munostained with CD4, CD8, B220, and F4/80 antibody as previ-
ously described (26) using the avidin-biotin-peroxidase detection
system (Vector Labs.). Glomerular macrophages were identified
in 4-
 
m
 
m acetone-fixed tissue sections using MOMA-2 antibody as
previously reported (16). Cells infiltrating within and around
(peri) glomeruli were assessed by counting the number of labeled
cells in 20 randomly selected glomeruli per section. The cells in-
filtrating around tubules were enumerated in 400 randomly se-
lected tubules per section. Macrophages and T cells within glo-
meruli, adjacent to glomeruli, or adjacent to cortical tubules were
expressed as a cell index (mean cell number/glomeruli 
 
3
 
 glomer-
uli/section; mean cell number/cortical tubule 3 cortical tubules/
section). Peribronchial and perivascular macrophages and T cells
(CD4, CD8, B220) in the lungs were assessed by measuring the
unit area stained/unit length of  bronchiole/vessel (five per ani-
mal) with a micrometer.
Detecting MCP-1 in Tissues. To detect MCP-1, formalin-fixed
sections were deparaffinized and incubated with 20% normal goat
serum for 30 min. Tissue sections were incubated with MCP-1
antibody (10 mg/ml) in 1% BSA overnight at 48C. Bound primary
antibody was labeled with biotin-conjugated goat anti–rabbit IgG
for 1 h and subsequently detected using the avidin-biotin-peroxi-
dase system (Vector Labs.). We confirmed MCP-1 antibody
specificity using two methods: (a) MCP-1 was not detectable in
tissue sections from MCP-1–deficient mice (negative control),
and (b) MCP-1 was expressed in Western blots of cell lysates
from LPS-stimulated bone marrow macrophages and mesangial
cells in MCP-1–intact but not MCP-1–deficient mice, as previ-
ously reported (21). Glomerular MCP-1 immunostaining was as-
sessed by the same scoring system used to detect glomerular infil-
trating cells. We analyzed MCP-1 in cortical tubules in 400
tubules per cross section. We enumerated the kidney and pulmo-
nary vessels and bronchioli that expressed MCP-1 in each section
and recorded values as the percent positive.
Serum Immunoglobulins Profile. ELISA plates were coated
overnight at 48C with 5 mg/ml goat anti–mouse Ig capture anti-
bodies (against total Ig, IgM, IgG1, IgG2a, IgG2b, and IgG3) in
0.1 M carbonate buffer, pH 9.4. Wells were blocked for 1 h with
assay diluent (2% BSA in 0.1 M borate buffer, pH 8.0). We then
added Ig standards to the plates (50 ml/well), starting at 1 mg/ml
and performing a series of threefold dilutions, and assessed serum
samples using serial (threefold) dilutions starting at 1:100 or 1:1,000.
Standards and serum samples were incubated overnight at 48C,
and bound Ig was detected with goat anti–mouse detection anti-
bodies conjugated with alkaline phosphatase and enzymatically
developed by incubating with Sigma 104 phosphatase substrate in
9.6% diethanolamine and 0.1 mM MgCl2, pH 9.8 (Sigma Chem-
ical Co.). Absorbance was measured at 405 nm.
IgG and C3 in Kidneys. To examine IgG and C3 deposits in
the kidney, we incubated cryostat-sectioned tissues (4 mm) with
20% normal goat or rabbit serum (30 min), followed by fluorescein-
conjugated antibodies detecting mouse IgG or mouse C3 (30 min),
washing, and mounting with Vectashield (Vector Labs.). We as-
sessed immunofluorescence staining by titrating the antibodies on
serial tissue sections using twofold dilution steps (1:100–1:25,600).
Apoptotic and Proliferating Cells In Situ. Apoptotic cells were
identified in tissue sections (4 mm) using the terminal deoxynucleo-
tide transferase–mediated dUTP-biotin nick-end labeling (TUNEL)
method and immunoperoxidase staining (In Situ Cell Death De-
tection Kit; Boehringer Mannheim). Proliferating cells were de-
tected by PCNA immunostaining as previously described (27).
Sections were counterstained with PAS reagent to determine mor-
phology. Apoptosis in glomeruli and tubules was assessed by
counting the number of TUNEL-labeled cells in 50 glomeruli per
section and 500 cortical tubules per section, respectively.
PCR Detection of MCPs and Cytokines in the Kidney. Total RNA
was extracted from the snap-frozen renal cortex of half a kidney
using RNAzol B (Tel-Test Inc.) and reverse transcribed using
oligo-dT and the Superscript II DNA preamplification kit (GIBCO
BRL). The resulting reverse transcription product was the cDNA
template for PCR analysis. GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) expression was detected as a 500-bp prod-
uct resulting from PCR with specific oligonucleotide primers
(antisense, 59-CAAAGTTGTCATGGATGACC-39; and sense,
59-GGTGGAGGTCGGAGTCAACG-39; reference 21). The
chemokines MCP-1, MCP-3, and MCP-5 were detected as 350-,
300-, and 370-bp PCR products, respectively, using specific oligo-
nucleotide primers (MCP-1 antisense, 59-GCTTGAGGTGGT-
TGTGGAAAA-39; MCP-1 sense, 59-CTCACCTGCTGCTAC-
TCATTC-39; MCP-3 antisense, 59-CACATTCCTACAGACAG-
CTC-39; MCP-3 sense, 59-AGCTACAGAAGGATCACCAG-39;
MCP-5 antisense, 59-CTCCTTATCCAGTATGGTCC-39; and
MCP-5 sense, 59-TCTCCCTCCACCATGCAGAG-39; refer-
ences 28–30). The cytokines IFN-g and CSF-1 were detected
as 500- and 245-bp PCR products using specific primers (IFN-g
sense, 59-CACGGCACAGTCATTGAAAGCC-39; IFN-g an-
tisense, 59-CTTATTGGGACAATCTCTTCCC-39; CSF-1 sense,
59-CACATGATTGGGAATGGACA-39; and CSF-1 antisense,
59-CAGCTGTTCAGGTTATTGGA-39; references 31 and 32).
The PCR primers and conditions were chosen so that the MCP
and GAPDH products were amplified with equal efficiency.
Statistics. Data was analyzed using the Kruskal-Wallis test for1816 Monocyte Chemoattractant Protein 1 Promotes Autoimmune Injury
comparing survival curves, the Mann-Whitney test to compare
group means, and Spearmans coefficient for correlations.
Results
Increased Expression of MCP-1 in MRL-Faslpr Tissues during
Autoimmune Disease. MCP-1 is upregulated in MRL-Faslpr
kidneys, lungs, and lymph nodes during autoimmune disease.
First, we detected an increase (threefold) in MCP-1 mRNA
within the renal cortex of wild-type pure MRL-Faslpr mice
as early as 2 mo of age, as compared with the C57BL/6
strain with normal kidneys. MCP-1 mRNA increased fur-
ther within the renal cortex (six- to eightfold) with advanc-
ing renal injury in these MRL-Faslpr mice (Fig. 1). We lo-
calized MCP-1 expression to several structures within the
MRL-Faslpr kidney and determined that the rank order of tis-
sue expression was tubules®glomeruli®vasculature. MCP-1
in MRL-Faslpr kidneys (5–6 mo of age) was almost exclu-
sively localized within the TECs. More specifically, MCP-1
was within the proximal TECs (brush border histologic
identification), whereas the distal TECs (histologic identifi-
cation) were only weakly positive or negative. MCP-1 ex-
pression in MRL-Faslpr glomeruli was determined to be
predominantly in epithelial podocytes, based on the mor-
phological positioning of MCP-1–stained cells in glomeruli
after histologic counterstaining (Fig. 2 b and Fig. 3 a),
whereas lesser amounts localized within the epithelial cells
and macrophages within crescents (two to three cells per
crescent). Finally, MCP-1 in the vasculature within endo-
thelial and smooth muscle cells was minimal (Fig. 3 a, insert).
It is noteworthy that few (1–2%) infiltrating cells in the renal
interstitium express MCP-1. Thus, kidney MCP-1 expres-
sion is almost exclusively within parenchymal cells and in
epithelial cells in particular, rather than infiltrating cells.
MCP-1 is expressed in other tissues in MRL-Faslpr mice
during autoimmune disease. Similar to MCP-1 in the kid-
ney, MCP-1 in the lungs is predominantly (.90%) expressed
in epithelial cells (bronchioli; Fig. 3 b) and is weakly de-
tected within vascular endothelial and interstitial cells in
MRL-Faslpr mice (5 mo of age). Massively enlarged lymph
nodes caused by an influx of T cells are characteristic of
MRL-Faslpr autoimmune disease (23). MCP-1 is readily
detected in cells surrounding lymphatic vessels within these
enlarged lymph nodes (inguinal, cervical) in MRL-Faslpr
mice (5 mo of age; Fig. 3 c). As anticipated, MCP-1 was
not detected in MCP-1–deficient MRL-Faslpr tissues (Fig. 3,
d–f). Taken together, these data indicate that MCP-1 is
mainly expressed by parenchymal cells in multiple tissues
targeted for autoimmune injury in MRL-Faslpr mice.
MCP-1–deficient MRL-Faslpr Mice Survive Longer than MCP-
1–intact MRL-Faslpr Mice and Are Protected from Proteinuria.
MCP-1–deficient MRL-Faslpr mice have a prolonged life
span as compared with MCP-1–intact MRL-Faslpr strains.
The vast majority of MCP-1–deficient MRL-Faslpr mice
(75%) remained alive at 300 d, as compared with a surviv-
ing minority of MCP-1–intact (MCP-11/1, 17% and
MCP-11/2, 44%) MRL-Faslpr mice (Fig. 4 a; P , 0.0001).
Notably, the mortality (50%) of the MCP-11/1 MRL-Faslpr
strain third generation was 7 mo of age, which is similar to
that of the pure wild-type MRL-Faslpr strain (6 mo of age)
Figure 1. MCP transcripts increase with advancing disease in MRL-
Faslpr kidneys. The renal cortex was isolated from C57BL/6 and MRL-
Faslpr kidneys from 2 to 6 mo of age and was analyzed for MCP-1, -3, and
-5 by reverse transcriptase (RT)-PCR. MCP-1, -3, and -5 are increased
in MRL-Faslpr kidneys with progressive disease. Examples of the amplified
PCR products are illustrated in the gel photos. Graph: data 5 mean 6
SD; n 5 3; *P , 0.01 vs. MRL-Faslpr (2 mo).
Figure 2. MCP-1 increases with advancing kidney disease in MRL-
Faslpr mice. MCP-1 was assessed by immunostaining in (a) cortical tu-
bules, (b) glomeruli, and (c) vessels in MRL-Faslpr kidneys. Data 5 mean 6
SD; *P , 0.05; **P , 0.005. (d) The relative proportion of MRL-Faslpr
kidney cells expressing MCP-1 was similar at 2, 4, and 6 mo of age. Few
infiltrating cells in the interstitium (#1%) express MCP-1.1817 Tesch et al.
and dissimilar to that of C57BL/6J and Sv/129 strains (.20
and 16 mo of age, respectively; reference 33).
It is important to note that the spot analysis for protein in
fresh individual urine specimens has several limitations, in-
cluding the sample size (volume) and semiquantitative mea-
surement. However, our confidence in making inferences
from this method is enhanced by the large number of mice
in each group and sequential monthly analysis. With these
Figure 3. MCP-1 expression in
MRL-Faslpr kidney, lung, and lymph
nodes. Tissues from MCP-1–intact
(a–c) and MCP-1–deficient (e and f)
MRL-Faslpr mice at 5 mo of age were
immunostained for MCP-1. MCP-1
is strongly expressed by TECs and
glomerular podocytes (a) but is weak
in vessels (inset) in MCP-1–intact
MRL-Faslpr kidneys. Bronchiolar
epithelial cells are the main source of
MCP-1 in MCP-1–intact MRL-
Faslpr lungs (b). A large proportion of
infiltrating cells surrounding lym-
phatics express MCP-1 within the
enlarged lymph nodes of MCP-1–
intact MRL-Faslpr mice (c). MCP-1
is not detected in MCP-1–deficient
kidney, lung, and lymph node (d–f).
a and d, 3800; b, c, e, and f, 3500.
Figure 4. MCP-1–deficient MRL-Faslpr mice
are protected from lethal autoimmune injury. (a)
We evaluated survival in MCP-1–intact (1/1,
1/2) and –deficient (2/2) MRL-Faslpr mice
(,50% male and female per group). The survival
of MCP-1–intact compared with –deficient
MRL-Faslpr mice is markedly reduced (P ,
0.0001). In addition, MCP-11/2  MRL-Faslpr
mice survive longer than the MCP-11/1 strain
(P , 0.0001). (b) As the collection of small daily
volumes of urine is compromised by evaporation
problems, we evaluated fresh urine samples using
a spot analysis. However, spot analysis in individ-
ual samples has several limitations, including
small sample volume and semiquantitative mea-
surement. With these caveats in mind, we now
report that MCP-1–deficient MRL-Faslpr mice
are protected from proteinuria (2–6 mo) in com-
parison to the MCP-1–intact MRL-Faslpr strain.
The number of surviving MCP-1–intact MRL-
Faslpr mice declines rapidly after 6 mo of age;
therefore, proteinuria at these ages is limited to a
subset of MCP-1–intact MRL-Faslpr mice,
which are more resistant to disease (normal 5
B6/129 wild type). (c) Lymphadenopathy is re-
duced in MCP-1–deficient MRL-Faslpr mice;
however, lymphadenopathy is greater in MCP-
1–intact MRL-Faslpr females as compared with
males (P , 0.01; females in graph). (d) Inflam-
matory skin lesions are reduced in MCP-1–defi-
cient compared with –intact strains. Data 5
mean 6 SEM; *P , 0.05; **P , 0.005; and
***P , 0.0001 compared with MCP-12/2.1818 Monocyte Chemoattractant Protein 1 Promotes Autoimmune Injury
caveats in mind, we now report that MCP-1–deficient ver-
sus MCP-1–intact MRL-Faslpr mice are protected from
pathological proteinuria. From 2 to 8 mo of age, both the
rate of increase and incidence of pathological proteinuria were
diminished in MCP-1–deficient MRL-Faslpr mice (Fig. 4 b).
For example, the vast majority (82%) of MCP-1–deficient
MRL-Faslpr mice had normal, nonpathologic proteinuria
(11), whereas the majority (62%) of MCP-1–intact MRL-
Faslpr mice were pathologically proteinuric (2–41) at 8 mo
of age. It should be noted that urinary protein in normal
B6/129 wild-type mice is barely detectable (0–11; data
not shown). Thus, MCP-1–deficient MRL-Faslpr mice are
protected from proteinuria.
Lymphadenopathy and Skin Lesions Are Reduced in MCP-1–
deficient MRL-Faslpr Mice.  We examined whether MCP-1
promotes autoimmune disease in the lymph nodes, spleen,
and skin of MRL-Faslpr mice from 3 to 8 mo of age. The in-
cidence and severity of lymphadenopathy and skin lesions
was reduced but not totally eliminated in MCP-1–deficient
as compared with MCP-1–intact MRL-Faslpr mice (Fig. 4, c
and d). For example, although nearly every MCP-1–intact
MRL-Faslpr mouse had palpable lymph nodes (94%), most
of the MCP-1–deficient mouse lymph nodes were not pal-
pable at 5 mo of age (69%). Similarly, the majority (84%) of
MCP-1–deficient mice were spared skin lesions, whereas
most (67%) of the MCP-1–intact MRL-Faslpr mice had gross
skin pathology at 8 mo of age. On the other hand, we did
not detect a difference in splenomegaly in MCP-1–defi-
cient (234 6 64 mg) versus MCP-1–intact MRL-Faslpr mice
(242 6 143 and 289 6 174 mg MCP-11/1 and MCP-11/2,
respectively; P 5 0.2; n 5 6 per group) at 5 mo of age.
Reduced Kidney and Lung Pathology in MCP-1–deficient
MRL-Faslpr Mice. To determine if MCP-1 is required for
kidney and lung pathology, we compared MCP-1–deficient
and –intact MRL-Faslpr mice killed at 5 mo of age. Renal
(tubular, glomerular) and pulmonary pathology was reduced
in MCP-1–deficient as compared with MCP-1–intact
MRL-Faslpr mice (Figs. 5 and 6). The reduction in tubular
and glomerular pathology assessed histologically was dramatic
(50–70%) in MCP-1–deficient MRL-Faslpr kidneys (Fig. 6, a
and b; P , 0.05). In particular, MCP-1–deficient MRL-
Faslpr mice had markedly diminished peritubular infiltrate,
tubular atrophy, glomerular hypercellularity, glomerulo-
sclerosis, and crescent formation. We further evaluated the
level of tubular and glomerular damage by identifying apop-
totic cells. The number of apoptotic cells was reduced in
MCP-1–deficient versus MCP-1–intact MRL-Faslpr kidneys.
The majority of apoptotic TECs diminished from 4.2 6
0.3% per section in MCP-1–intact to 2.0 6 0.6% per sec-
tion in MCP-1–deficient MRL-Faslpr kidneys (P , 0.05; n 5
6 per group). Similarly, the number of apoptotic glomeru-
lar cells was reduced in MCP-1–deficient versus MCP-1–
Figure 5. Kidney and lung his-
topathology are reduced in MCP-
1–deficient MRL-Faslpr mice. Tubular
damage (arrowheads) and glomeru-
lar crescents (arrow) are severe in
MCP-1–intact MRL-Faslpr kidneys
(a; hematoxylin and PAS) and are
reduced in the MCP-1–deficient
MRL-Faslpr strain (b) at 5 mo of age.
Peribronchial and perivascular cell
infiltration in MRL-Faslpr lungs are
prominent in the MCP-1 (1/1)
strain at 5 mo of age (c). By com-
parison, the peribronchial infiltrate
is reduced in the MCP-1 (2/2)
MRL-Faslpr strain (d). a and b, 3800;
c and d, 3500.1819 Tesch et al.
intact mice (0.11 6 0.04 cells/gcs and 0.25 6 0.05 cells/
gcs, respectively; P , 0.05; n 5 6 per group). Although
there was a reduction in tubular and glomerular pathology
in MCP-1–deficient MRL-Faslpr kidneys, it was not totally
prevented (Fig. 6, a and b) in comparison to age-matched
kidneys from MRL11 and C3H mice with normal kidneys
(Fig. 6, a and b; P , 0.005). There was an increase in tubu-
lar and glomerular pathology in MCP-1–deficient MRL-
Faslpr kidneys. In contrast to the protection afforded by the
absence of MCP-1 in renal tubules and glomeruli of MRL-
Faslpr mice, the perivascular infiltrates in MCP-1–deficient
and –intact MRL-Faslpr kidneys remained similar (Fig. 6 c).
Thus, MCP-1 is responsible for tubular and glomerular but
not perivascular renal pathology.
Pulmonary disease was reduced in MCP-1–deficient
versus MCP-1–intact MRL-Faslpr mice. Lung pathology in
MCP-1–intact MRL-Faslpr mice consists of infiltrating cells
predominantly surrounding bronchioles and vasculature.
The numbers of cells surrounding bronchioles in MCP-1–
deficient versus MCP-1–intact MRL-Faslpr strains was dra-
matically reduced (Fig. 6 d and Fig. 7, d–f; P , 0.02). As in
the kidney, the infiltrating cells surrounding vessels were
not reduced in MCP-1–deficient versus MCP-1–intact
MRL-Faslpr lungs (Fig. 6 e; P 5 0.15).
Less Kidney Pathology in MCP-1–deficient versus MCP-1–
intact MRL-Faslpr Mice that Do Not Survive. We determined
if the MCP-1–deficient MRL-Faslpr mice that died (25%;
300 d) developed renal injury that was as severe as that of
the MCP-1–intact MRL-Faslpr mice that succumbed at con-
siderably younger ages (83% mortality; 300 d; Fig. 4 a). The
MCP-1–deficient MRL-Faslpr mice had less (40–50%) tu-
bular and glomerular pathology compared with the MCP-1–
intact MRL-Faslpr kidneys (P , 0.05; n 5 6; data not
shown). In addition, fewer (5/11) MCP-1–deficient MRL-
Faslpr mice, as compared with MCP-1–intact MRL-Faslpr
mice (12/16), died with severe proteinuria (3–41). Thus,
even in the MCP-1–deficient and MCP-1–intact MRL-
Faslpr mice that eventually die, the extent of renal injury is
less severe in the MCP-1–deficient MRL-Faslpr strain.
Decreased Infiltrating Cells in the Kidney (Macrophages and T
Cells) and Lungs (Macrophages) in MCP-1–deficient versus
MCP-1–intact MRL-Faslpr Mice. There was a reduction in
the number of macrophages and T cells (CD4 and CD8
but not B220) in MCP-1–deficient versus MCP-1–intact
MRL-Faslpr kidneys. The majority of macrophages and T
cells localized in the interstitium adjacent to tubules and
glomeruli, whereas fewer were identified within glomeruli.
We noted the largest (50–72%) decline in macrophages and
T cells in the MCP-1–deficient MRL-Faslpr strain surround-
ing tubules (P , 0.01; Fig. 7, a–c), a reduction that corre-
lated with the extent of tubular injury (r  $ 0.80; P ,
0.005). Periglomerular macrophages and CD4 but not CD8
T cells were also diminished (45–53%, P , 0.05) in MCP-1–
deficient MRL-Faslpr mice (Fig. 7 a). Although intraglo-
merular macrophages were reduced (34%) in MCP-1–defi-
cient MRL-Faslpr kidneys (P , 0.005; Fig. 7 a), the numbers
of intraglomerular T cells (CD4, CD8, B220) were not
diminished (P 5 0.2). The reduction in glomerular macro-
phages correlated with diminished glomerular morphologic
damage (intraglomerular, r 5 0.78; periglomerular, r 5 0.77;
P , 0.005). The absence of MCP-1 in MRL-Faslpr lungs
reduced the number of infiltrating macrophages surround-
ing bronchioli but not surrounding vessels (Fig. 7, d–f). In
contrast to the reduction in the number of kidney-infiltrat-
ing T cells in MCP-1–deficient versus –intact MRL-Faslpr
mice, the number of T cells (CD4, CD8, B220) in the
lungs was not reduced (P 5 0.2; Fig. 7 d).
A Reduction in Macrophages and T Cells in MCP-1–deficient
Kidneys and Lungs Did Not Result from Decreased Local Prolifera-
tion. We determined if the decreased accumulation of
macrophages and T cells in MCP-1–deficient MRL-Faslpr
kidneys and lungs at 5 mo of age was a result of a decline in
local proliferation using in situ detection of PCNA. First,
few of the cells surrounding tubules (,1%), glomeruli
(,1%), and bronchioli (,10%) were proliferating in the
MCP-1–intact MRL-Faslpr strain. The number of PCNA1
cells was not reduced in the MCP-1–deficient MRL-Faslpr
strain (P 5 0.2; n 5 6). Second, there were substantially
more proliferating cells surrounding vessels (.20%) com-
Figure 6. MCP-1–deficient MRL-Faslpr mice are protected from kid-
ney and lung damage during renal disease. MCP-1 intact (1/1, 1/2)
and deficient (2/2) MRL-Faslpr kidneys were assessed for (a) tubular
damage, (b) glomerular damage, and (c) perivascular cell infiltrate at 5 mo
of age and compared with age-matched wild-type MRL11 C3H/FeJ
strains. MCP-1–intact (1/1,  1/2) and deficient (2/2) MRL-Faslpr
lungs were analyzed for (d) peribronchiolar and (e) perivascular cell infil-
trate at 5 mo of age. Kidney (tubular and glomerular) and lung (bronchi-
olar) pathology but not vasculitis was reduced in MCP-1–deficient versus
MCP-1–intact MRL-Faslpr mice. Data 5 mean 6 SD.1820 Monocyte Chemoattractant Protein 1 Promotes Autoimmune Injury
pared with proliferating cells surrounding glomeruli, tu-
bules, and bronchioles in MCP-1–intact MRL-Faslpr kid-
neys and lungs (P , 0.002), and this number did not
decrease in the MCP-1–deficient MRL-Faslpr strain (P 5
0.1; n 5 6 per group). Of course, it must be appreciated
that the proliferation measurements in tissue sections are a
reflection of the level of cell division at the time these tissues
were removed. Thus, the reduction in kidney- and lung-infil-
trating cells in MCP-1–deficient MRL-Faslpr mice does not
appear to result from decreased local proliferation.
CCR2 Ligand Expression in MCP-1–deficient MRL-Faslpr
Kidneys Is Decreased. MCPs 1–5 are ligands for the MCP-1
receptor (CCR2; reference 22). To examine whether CCR2
ligands other than MCP-1 are upregulated after renal in-
jury, we examined MCP-3 and MCP-5 in MRL-Faslpr kid-
neys. Renal cortical transcripts of MCP-3 and MCP-5 in
MRL-Faslpr as compared with C57BL/6 mice were increased
(twofold) in advance of overt renal pathology (2 mo of age)
and rose further (fourfold) as renal pathology advanced (6 mo
of age; Fig. 1). We probed for MCP expression in MCP-1–
deficient MRL-Faslpr kidneys. As anticipated, MCP-1 tran-
scripts were not detected in the MCP-1–deficient MRL-
Faslpr renal cortex. On the other hand, MCP-3 and MCP-5
transcripts were detected in MCP-1–deficient MRL-Faslpr
mice (Fig. 8). However, amounts of MCP-3 and MCP-5
transcripts were 50% lower in MCP-1–deficient versus
MCP-1–intact MRL-Faslpr  kidneys (P , 0.005; Fig. 8).
Thus, MRL-Faslpr mice lacking MCP-1 have reduced in-
trarenal productions of ligands (MCP-3, MCP-5) that bind
to CCR2.
Reduced CSF-1 and IFN-g Transcripts in MCP-1–deficient
MRL-Faslpr Kidneys. We previously established that CSF-1
and IFN-g transcripts that are upregulated with advancing
renal injury in MRL-Faslpr mice are required for autoim-
mune kidney disease (25, 34, 35). In MCP-1–deficient MRL-
Faslpr kidneys, CSF-1 and IFN-g transcripts were reduced
as compared with the MCP-1 intact MRL-Faslpr strain (Fig.
Figure 7. Kidney- and lung-infil-
trating leukocytes are reduced in
MCP-1–deficient MRL-Faslpr mice.
Infiltrating leukocytes were assessed in
the kidney (a–c) and lung (d–f) by
immunostaining. Macrophage (MØ)
accumulation adjacent to kidney
parenchymal cells (peritubular, peri-
glomerular, intraglomerular) in MCP-
1–intact MRL-Faslpr mice (b) is mark-
edly reduced in MCP-1–deficient
MRL-Faslpr mice (c). Similarly, the
notable macrophage accumulation ad-
jacent to parenchymal cells in the lung
(peribronchiolar) in MCP-1–intact
MRL-Faslpr mice (e) is dramatically
less in MCP-1–deficient MRL-Faslpr
mice (f). Furthermore, T cells, includ-
ing CD4 and CD8 T cells, are re-
duced in the peritubular area, whereas
CD4 T cells accumulate less surround-
ing glomeruli in MCP-1–deficient
versus MCP-1–intact MRL-Faslpr
strains (a). In contrast, perivascular
macrophages and T cells are not differ-
ent in the MCP-1–intact and –defi-
cient MRL-Faslpr lungs (d) and kid-
neys (not shown). Data 5 mean 6
SD; n 5 6; *P , 0.05 and **P , 0.01
compared with MCP-11/1. F4/80
immunostaining: b and c, 3500; e and
f, 3330.
Figure 8. MCP-1 deficiency reduces CSF-1, IFN-g, and other CCR2
ligands in MRL-Faslpr kidneys. Transcript levels of CSF-1, IFN-g, MCP-3,
and MCP-5 were assessed in comparison to GAPDH in MCP-1–intact
and –deficient MRL-Faslpr and B6/129 mouse renal cortices at 5 mo of
age by RT-PCR. CSF-1, IFN-g, MCP-3, and MCP-5 transcripts were
reduced in MCP-1–deficient versus MCP-1–intact MRL-Faslpr mice.
Data 5 mean 6 SD; n 5 6; P values compared with MCP-1–intact
MRL-Faslpr mice.1821 Tesch et al.
8). In contrast, CSF-1 and IFN-g transcripts in MCP-1–
deficient and –intact B6/129 mice with normal kidneys were
barely detectable (Fig. 8).
Serum- and Kidney-deposited Igs Are Not Reduced in MCP-1–
deficient MRL-Faslpr Mice. To determine if MCP-1 alters
the antibody isotype profile in MRL-Faslpr autoimmune
disease, we evaluated serum levels of IgGs (total Ig, IgM,
IgG1, IgG2a, IgG2b, IgG3) in MCP-1–deficient and –intact
MRL-Faslpr mice. We did not detect differences in serum
IgGs (amount and isotype) in MCP-1–deficient and –intact
MRL-Faslpr strains (Fig. 9 a). In addition, we did not detect
an alteration in the amount and distribution of Igs within
MCP-1–deficient and –intact MRL-Faslpr kidneys (Fig. 9 b).
Similarly, complement (C3) deposition was not reduced in
MCP-1–deficient as compared with MCP-1–intact MRL-
Faslpr glomeruli (data not shown). Thus, MCP-1 does not
regulate circulating or kidney-depositing IgGs in MRL-
Faslpr mice.
Discussion
In this report, we tested the hypothesis that a specific
chemokine, MCP-1, is required for autoimmune tissue
injury in MRL-Faslpr mice. We now report that MRL-
Faslpr mice genetically deficient in MCP-1 are partially pro-
tected from autoimmune disease, including injury to the
kidney, lung, and skin and lymphadenopathy, resulting in a
prolonged life span. Protection against tissue injury in
MCP-1–deficient MRL-Faslpr mice results from a reduced
infiltration of leukocytes (macrophages and T cells) toward
parenchymal cells that no longer express MCP-1 and a
diminution in cytokines known to promote tissue injury.
Furthermore, we determined that the accumulation of
these cells is a result of recruitment, but not proliferation,
toward the parenchymal cells in proportion to MCP-1 ex-
pression. Thus, MCP-1 is responsible for recruiting mac-
rophages and T cells into multiple tissues, including the
kidney, lung, and lymph nodes, in MRL-Faslpr mice, which
in turn results in autoimmune tissue destruction.
During inflammation, multiple parenchymal and leuko-
cyte cell types express MCP-1 (36). Our challenge was to
identify the cell types and locations expressing MCP-1 and
determine the impact of cells producing MCP-1 on disease
progression in MRL-Faslpr mice. We now report that MCP-1
is primarily expressed by parenchymal cells, and not infil-
trating cells, in MRL-Faslpr mice, beginning before and
then increasing during autoimmune disease. We determined
that parenchymal epithelial cells express far more MCP-1
than other parenchymal cell types (endothelial cells, smooth
muscle cells, and mesangial cells). Furthermore, we estab-
lished that the accumulation of macrophages and T cells
was directly proportional to MCP-1 expression by these
parenchymal cells. This is consistent with our previous
findings in a rapid, induced form of kidney damage, NSN,
consisting of glomerular and tubular pathology (21). In NSN,
we noted that MCP-1, abundantly expressed in TECs and
barely detected in glomeruli, was responsible for tubular
but not glomerular injury. We established that macrophages
were recruited toward tubules expressing MCP-1 and after
activation released molecules that induced TEC apoptosis
(21). By comparison, the importance of MCP-1 in pro-
gressive autoimmune disease in MRL-Faslpr mice is broader
than in NSN. First, MCP-1 is responsible for the accumu-
lation of not only macrophages but also T cells within the
kidney (tubules and glomeruli) and other tissues (lungs and
lymph nodes) during autoimmune disease in MRL-Faslpr
mice. For example, massively enlarged lymph nodes, com-
posed of T cells, are characteristic of MCP-1–intact MRL-
Faslpr mice (37). The most convincing evidence for MCP-1
fostering T cell accumulation is highlighted by the substan-
tial decrease in the incidence of lymphadenopathy and
lymph node size (.50% reduced at 8 mo of age) in MCP-1–
deficient MRL-Faslpr mice. However, the numbers of T
cells in the MCP-1–deficient MRL-Faslpr lymph nodes are
not reduced to normal levels. In addition, MCP-1 is not
required for splenomegaly in MRL-Faslpr spleens, as MCP-1–
intact and MCP-1–deficient MRL-Faslpr spleens were sim-
ilar. Thus, MCP-1 is responsible in part for lymphadenopa-
thy, but other molecules, perhaps chemokines, are required
for splenomegaly in the MRL-Faslpr strain. Other candidates
that are likely to be involved in splenomegaly include the
b-chemokines macrophage inflammatory protein (MIP)-1a
and MIP-1b, reported to foster T cell trafficking (CD4,
CD8) into lymph nodes after induced hypersensitivity (38).
In addition, we suggest that the broader impact of MCP-1
on kidney injury in the MRL-Faslpr mouse versus NSN is
related to the progressive accumulation of MCP-1–depen-
dent leukocytes over a longer period of disease manifesta-
tion in the MRL-Faslpr kidney and other tissues. Further-
more, comparison of MCP-1 immunostaining and mRNA
levels in the two models indicates that tubules and glomer-
uli in MCP-1–intact MRL-Faslpr mice (5–6 mo) express
higher amounts of MCP-1 than in NSN (7 d). Disease in
NSN is mostly limited to the kidney, whereas MRL-Faslpr
mice have multiple tissues targeted for destruction, each
expressing MCP-1. Thus, by gene target–deleting MCP-1
in MRL-Faslpr mice, we determined that MCP-1 is respon-
sible for recruiting macrophages and T cells to numerous
tissues, each undergoing autoimmune disease.
Figure 9. (a) MCP-1 deficiency does not reduce serum Ig isotype lev-
els in MRL-Faslpr mice. Serum from MCP-1–intact and –deficient MRL-
Faslpr mice at 5 mo of age was analyzed for Igs by ELISA. (b) MCP-1–
deficient MRL-Faslpr mice (5 mo of age) have equivalent amounts of IgG
and C3 (not shown) in the kidney despite a reduction in loss of renal
function, glomerular and tubular injury, and enhanced survival as com-
pared with the MCP-1–intact strain. Data 5 mean 6 SD; n 5 6.1822 Monocyte Chemoattractant Protein 1 Promotes Autoimmune Injury
The accumulation of macrophages and T cells surround-
ing parenchymal tissue in MRL-Faslpr mice results from re-
cruitment and/or proliferation of these leukocytes (26, 27,
34, 35, 39). As MCP-1 induces IL-2 production by T cells
(14), it is possible that MCP-1 promotes T cell prolifera-
tion in the kidney, lung, and lymph nodes. However, as
few infiltrating cells are proliferating (PCNA1) at sites of
MCP-1 expression within the kidney, lung, and enlarged
lymph nodes in MRL-Faslpr mice, we conclude that the
primary action of MCP-1 is to recruit macrophages and T
cells into tissues and thereby promote autoimmune disease.
To further support the concept that MCP-1 initiates
kidney injury via recruitment and not other immune events,
we investigated whether MCP-1 caused an Ig isotype
switch and alteration in Ig deposition in the kidney. Ele-
vated Ig levels in MRL-Faslpr mice are dependent on T cell
(40) and B cell (41, 42) events that are independent of
MCP-1 in MRL-Faslpr mice. In addition, isotypes such as
IgG3 compromise glomerular function (43). We did not
detect any difference in the serum Ig isotypes nor in the
amount or location of Igs in the kidney. It is interesting to
note that despite the similarly high levels of serum and
glomerular Igs, the glomeruli are better preserved function-
ally (loss of protein) and structurally in MCP-1–deficient
versus MCP-1–intact MRL-Faslpr mice. This suggests that,
even when the Igs are deposited within the kidney, MCP-1
is required to attract leukocytes into the kidney to initiate
glomerular and tubular/interstitial renal disease in MRL-
Faslpr mice.
Protection from injury in MCP-1–deficient MRL-Faslpr
kidneys is associated with reduced number of transcripts of
the nephritogenic cytokines (IFN-g and CSF-1) and other
chemokines in addition to MCP-1 that bind to the CCR2
receptor (MCP-3 and MCP-5). This could be either di-
rectly or indirectly related to the MCP-1 deletion in MRL-
Faslpr mice. For example, MCP-1 immunomodulation of
CD4 cells is related to the release of IFN-g (14). We sug-
gest that after MCP-1–dependent recruitment of leuko-
cytes into the kidney, a cascade of events triggers the pro-
duction of IFN-g, CSF-1, MCP-3, and MCP-5, which
each contribute to autoimmune kidney damage. For exam-
ple, we have previously established that CSF-1, a macro-
phage growth factor, is responsible for promoting macro-
phage- and T cell–initiated kidney injury (35), whereas
IFN-g, with more complex actions, either thwarts (27) or
fosters (25, 44) injury depending on when it is expressed
during disease. In addition, MCP-3 and MCP-5 may be
responsible for the migration of leukocytes into the kidney
(45). We therefore speculate that the increase in MCP-1 is
a proximal stimulus responsible for recruiting macrophages
and T cells, which in turn are responsible for triggering the
production of cytokines and other chemokines that lead to
tissue injury.
Although MCP-1 depletion dampens injury in multiple
tissues during autoimmune attack, these tissues are not to-
tally protected. The kidneys, lungs, spleen, lymph nodes, and
skin do not remain normal. The renal tubule/interstitium,
glomeruli, lungs, and lymph nodes in MCP-1–deficient
MRL-Faslpr mice are still invaded by leukocytes, although
in far lower numbers than in MCP-1–intact MRL-Faslpr mice.
Additionally, the limited number of MCP-1–deficient
MRL-Faslpr mice that do not survive kidney glomerular and
tubular disease and proteinuria is far lower than younger
MCP-1–intact MRL-Faslpr mice that succumb. In contrast,
vascular disease is not prevented in MCP-1–deficient kid-
neys and lungs. The accumulation of leukocytes around ves-
sels, almost exclusively T cells, is just as abundant in MCP-1–
deficient versus –intact MRL-Faslpr kidneys and lungs.
There are several possible explanations for this finding. Other
chemokines may be responsible for recruiting these infil-
trating leukocytes. For example, MCP-1 is weakly ex-
pressed in the vascular wall and perivascular leukocytes,
whereas RANTES (regulated upon activation, normal T
cell expressed and secreted) is abundant in both areas (data
not shown). In addition, many perivascular leukocytes in
the kidney and lung are proliferating (PCNA1) and, there-
fore, perivascular leukocytes may accumulate because of lo-
cal proliferation. It is worth noting that perivasculitis in the
kidney contributes to mortality in wild-type MRL-Faslpr
mice (45, 46) and, therefore, may be at least partially com-
promising in several tissues in MCP-1–deficient MRL-
Faslpr mice. Finally, as the accumulation of leukocytes in
the renal interstitium is focal in both MCP-1–intact and
–deficient MRL-Faslpr mice, we suggest that molecules re-
sponsible for adhesion, cell activation, proliferation, and death,
including integrins, selectins, and cytokines, may contrib-
ute to this process. Furthermore, we cannot rule out the
possibility that other chemokines, in addition to MCP-1,
enhance leukocytic recruitment. Thus, to achieve more com-
plete  protection from autoimmune disease in the MRL-
Faslpr strain, we will have to identify additional therapeutic
targets.
In conclusion, we suggest that MCP-1 is a therapeutic
target to combat autoimmune/inflammatory diseases trig-
gered by tissue leukocytic invasion. Our data further sug-
gest that eliminating MCP-1 expression does not confer
total protection. It is thus critical to identify the other ther-
apeutic targets responsible for leukocyte invasion and ex-
pansion to confer total protection.
We wish to thank Dr. Hyung-Jin Yoon for assisting with the construction of the MCP-1–deficient MRL-
Faslpr strain.
This work was supported in part by National Institutes of Health grants DK-36149 and DK 52369 (to V.R.
Kelley) and a research fellowship from the National Kidney Foundation (to G.H. Tesch).1823 Tesch et al.
Address correspondence to Vicki Rubin Kelley, Harvard Institutes of Medicine, 77 Ave. Louis Pasteur,
Boston, MA 02115. Phone: 617-525-5915; Fax: 617-525-5830; E-mail: vkelley@rics.bwh.harvard.edu
Submitted: 20 April 1999 Revised: 27 September 1999 Accepted: 5 October 1999
References
1. Koh, D.R., A. Ho, A. Rahemtulla, W.P. Fung-Leung, H.
Griesser, and T.W. Mak. 1995. Murine lupus in MRL/lpr mice
lacking CD4 or CD8 T cells. Eur. J. Immunol. 25:2558–2562.
2. Tran, E.H., K. Hoekstra, N. van Rooijen, C.D. Dijkstra, and
T. Owens. 1998. Immune invasion of the central nervous sys-
tem parenchyma and experimental allergic encephalomyelitis,
but not leukocyte extravasation from blood, are prevented in
macrophage-depleted mice. J. Immunol. 161:3767–3775.
3. Rovin, B.H., M. Rumancik, L. Tan, and J. Dickerson. 1994.
Glomerular expression of monocyte chemoattractant pro-
tein-1 in experimental and human glomerulonephritis. Lab.
Invest. 71:536–542.
4. Wada, T., H. Yokoyama, S. Su, N. Mukaida, M. Iwano, K.
Dohi, Y. Takahashi, T. Sasaki, K. Furuichi, C. Segawa, et al.
1996. Monitoring urinary levels of monocyte chemotactic
and activating factor reflects disease activity of lupus nephri-
tis. Kidney Int. 49:761–767.
5. Harigai, M., M. Hara, T. Yoshimura, E.J. Leonard, K. Inoue,
and S. Kashiwazaki. 1993. Monocyte chemoattractant pro-
tein-1 (MCP-1) in inflammatory joint diseases and its in-
volvement in the cytokine network of rheumatoid syno-
vium.  Clin. Immunol. Immunopathol. 69:83–91.
6. Zoja, C., X.H. Liu, R. Donadelli, M. Abbate, D. Testa, D.
Corna, G. Taraboletti, A. Vecchi, Q.G. Dong, B.J. Rollins,
et al. 1997. Renal expression of monocyte chemoattractant
protein-1 in lupus autoimmune mice. J. Am. Soc. Nephrol.
8:720–729.
7. Berman, J.W., M.P. Guida, J. Warren, J. Amat, and C.F.
Brosnan. 1996. Localization of monocyte chemoattractant
peptide-1 expression in the central nervous system in experi-
mental autoimmune encephalomyelitis and trauma in the rat.
J. Immunol. 156:3017–3023.
8. Valente, A.J., D.T. Graves, C.E. Vialle-Valentin, R. Del-
gado, and C.J. Schwartz. 1988. Purification of monocyte
chemotactic factor secreted by nonhuman primate vascular
cells in culture. Biochemistry. 27:4162–4168.
9. Carr, M.W., S.J. Roth, E. Luther, S.S. Rose, and T.A.
Springer. 1994. Monocyte chemoattractant protein-1 acts as
a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. USA.
91:3652–3656.
10. Allavena, P., G. Bianchi, D. Zhou, J. Van Damme, P. Jilek,
S. Sozzani, and A. Mantovani. 1994. Induction of natural
killer cell migration by monocyte chemotactic protein-1, -2
and -3. Eur. J. Immunol. 24:3233–3236.
11. Jiang, Y., D.I. Beller, G. Frendl, and D.T. Graves. 1992.
Monocyte chemoattractant protein-1 regulates adhesion
molecule expression and cytokine production in human
monocytes. J. Immunol. 148:2423–2428.
12. Kim, J.J., L.K. Nottingham, J.I. Sin, A. Tsai, L. Morrison, J.
Oh, K. Dang, Y. Hu, K. Kazahaya, M. Bennett, et al. 1998.
CD8 positive T cells influence antigen-specific immune re-
sponses through the expression of chemokines. J. Clin. Invest.
102:1112–1124.
13. Hogaboam, C.M., N.W. Lukacs, S.W. Chensue, R.M. Strei-
ter, and S.L. Kunkel. 1998. Monocyte chemoattractant pro-
tein-1 synthesis by murine lung fibroblasts modulates CD41
T cell activation. J. Immunol. 160:4606–4614.
14. Taub, D.D., J.R. Ortaldo, S.M. Turcovski-Corrales, M.L.
Key, D.L. Longo, and W.J. Murphy. 1996. b Chemokines
costimulate lymphocyte cytolysis, proliferation, and lym-
phokine production. J. Leukoc. Biol. 59:81–89.
15. Gong, J.H., L.G. Ratkay, J.D. Waterfield, and I. Clark-
Lewis. 1997. An antagonist of monocyte chemoattractant
protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse
model. J. Exp. Med. 186:131–137.
16. Lloyd, C.M., A.W. Minto, M.E. Dorf, A. Proudfoot, T.N.C
Wells, D.J. Salant, and J.C. Gutierrez-Ramos. 1997.
RANTES and monocyte chemoattractant protein-1 (MCP-1)
play an important role in the inflammatory phase of crescen-
tic nephritis, but only MCP-1 is involved in crescent forma-
tion and interstitial fibrosis. J. Exp. Med. 185:1371–1380.
17. Smith, R.E., R.M. Streiter, K. Zhang, S.H. Phan, T.J. Standi-
ford, N.W. Lukacs, and S.L. Kunkel. 1995. A role for C-C
chemokines in fibrotic lung disease. J. Leukoc. Biol. 57:782–787.
18. Lukacs, N.W., R.M. Strieter, K. Warmington, P. Lincoln,
S.W. Chensue, and S.L. Kunkel. 1997. Differential recruit-
ment of leukocyte populations and alteration of airway hy-
perreactivity by C-C family chemokines in allergic airway in-
flammation. J. Immunol. 158:4398–4404.
19. Gonzalo, J.A., C.M. Lloyd, D. Wen, J.P. Albar, T.N. Wells,
A. Proudfooot, A.C. Martinez, M. Dorf, T. Bjerke, A.J.
Coyle, et al. 1998. The coordinated action of CC chemo-
kines in the lung orchestrates allergic inflammation and air-
way hyperresponsiveness. J. Exp. Med. 188:157–167.
20. Lu, B., B.J. Rutledge, L. Gu, J. Fiorillo, N.W. Lukacs, S.L.
Kunkel, R. North, C. Gerard, and B.J. Rollins. 1998. Ab-
normalities in monocyte recruitment and cytokine expression
in monocyte chemoattractant protein 1–deficient mice. J.
Exp. Med. 187:601–608.
21. Tesch, G.H., A. Schwarting, K. Kinoshita, H.Y. Lan, B.J.
Rollins, and V. Rubin Kelley. 1999. MCP-1 promotes mac-
rophage-mediated tubular injury, but not glomerular injury,
in nephrotoxic serum nephritis. J. Clin. Invest. 103:73–80.
22. Rollins, B.J. 1997. Chemokines. Blood. 90:909–928.
23. Theofilopoulos, A.N., and F.J. Dixon. 1985. Murine models
of systemic lupus erythematosus. Adv. Immunol. 37:269–390.
24. Wu, J., T. Zhou, J. He, and J.D. Mountz. 1993. Autoim-
mune disease in mice due to integration of an endogenous
retrovirus in an apoptosis gene. J. Exp. Med. 178:461–468.
25. Schwarting, A., T. Wada, K. Kinoshita, G. Tesch, and V.R.
Kelley. 1998. IFN-g receptor signaling is essential for the ini-
tiation, acceleration, and destruction of autoimmune kidney
disease in MRL-Faslpr mice. J. Immunol. 161:494–503.
26. Moore, K.J., T. Naito, C. Martin, and V.R. Kelley. 1996.
Enhanced response of macrophages to CSF-1 in autoimmune
mice. A gene transfer strategy. J. Immunol. 157:433–440.
27. Schwarting, A., K. Moore, T. Wada, G. Tesch, H.J. Yoon,
and V. Rubin Kelley. 1998. IFN-g limits macrophage ex-1824 Monocyte Chemoattractant Protein 1 Promotes Autoimmune Injury
pansion in MRL-Faslpr autoimmune interstitial nephritis: a
negative regulatory pathway. J. Immunol. 160:4074–4081.
28. Lukacs, N.W., S.W. Chensue, R.E. Smith, R.M. Strieter, K.
Warmington, C. Wilke, and S.L. Kunkel. 1994. Production
of monocyte chemoattractant protein-1 and macrophage in-
flammatory protein-1 alpha by inflammatory granuloma fi-
broblasts. Am. J. Pathol. 144:711–718.
29. Natori, Y., M. Sekiguchi, Z. Ou, and Y. Natori. 1997. Gene
expression of CC chemokines in experimental crescentic
glomerulonephritis (CGN). Clin. Exp. Immunol. 109:143–148.
30. Jia, G.Q., J.A. Gonzalo, C. Lloyd, L. Kremer, L. Lu, A.C.
Martinez, B.K. Wershil, and J.C. Gutierrez-Ramos. 1996.
Distinct expression and function of the novel mouse
chemokine monocyte-chemoattractant protein-5 in lung al-
lergic inflammation. J. Exp. Med. 184:1939–1951.
31. O’Connell, P.J., A. Pacheco-Silva, P.W. Nickerson, R.A.
Muggia, M. Bastos, V.R. Kelley, and T.B. Strom. 1993. Un-
modified pancreatic islet allograft rejection results in the pref-
erential expression of certain T cell activation transcripts. J.
Immunol. 150:1093–1104.
32. Ezure, T., T. Ishiwata, G. Asano, S. Tanaka, and K. Yoko-
mura. 1997. Production of macrophage colony-stimulating
factor by murine liver in vivo. Cytokine. 9:53–58.
33. Russell, E.S. 1968. The Jackson Laboratory’s Pedigreed Ex-
pansion Stocks. Lifespan and Aging Patterns. Biology of the
Laboratory Mouse. E.A. Green, editor. Dover Publications,
Inc., New York. 512 pp.
34. Bloom, R.D., S. Florquin, and V.R. Kelley. 1993. Colony
stimulating factor-1 in the induction of lupus nephritis. Kid-
ney Int. 43:1000–1009.
35. Naito, T., H. Yokoyama, K.J. Moore, G. Dranoff, R.C.
Mulligan, and V.R. Kelley. 1996. Macrophage growth fac-
tors introduced into the kidney initiate renal injury. Mol.
Med. 2:297–312.
36. Rovin, B.H., and L.T. Phan. 1998. Chemotactic factors and
renal inflammation. Am. J. Kidney Dis. 31:1065–1084.
37. Watanabe-Fukunaga, R., C.I. Brannan, N.G. Copeland,
N.A. Jenkins, and S. Nagata. 1992. Lymphoproliferation dis-
order in mice explained by defects in Fas antigen that medi-
ates apoptosis. Nature. 356:314–317.
38. Tedla, N., H.W. Wang, H.P. McNeil, N. Di Girolamo, T.
Hampartzoumian, D. Wakefield, and A. Lloyd. 1998. Regu-
lation of T lymphocyte trafficking into lymph nodes during
an immune response by the chemokines macrophage inflam-
matory protein (MIP)-1 alpha and MIP-1 beta. J. Immunol.
161: 5663–5672.
39. Moore, K.J., T. Wada, S.D. Barbee, and V.R. Kelley. 1998.
Gene transfer of RANTES elicits autoimmune renal injury in
MRL-Fas(lpr) mice. Kidney Int. 53:1631–1641.
40. Santoro, T.J., J.P. Portanova, and B.L. Kotzin. 1988. The
contribution of L3T41 T cells to lymphoproliferation and
autoantibody production in MRL-lpr/lpr mice. J. Exp. Med.
167:1713–1718.
41. Sobel, E.S., T. Katagiri, K. Katagiri, S.C. Morris, P.L. Co-
hen, and R.A. Eisenberg. 1991. An intrinsic B cell defect is
required for the production of autoantibodies in the lpr
model of murine systemic autoimmunity. J. Exp. Med. 173:
1441–1449.
42. Merino, R., M. Iwamoto, L. Fossati, and S. Izui. 1993. Poly-
clonal B cell activation arises from different mechanisms in lu-
pus-prone (NZB 3 NZW)F1 and MRL/Mpj-lpr/lpr mice. J.
Immunol. 151:6509–6516.
43. Izui, S., T. Berney, T. Shibata, and T. Fulpius. 1993. IgG3
cryoglobulins in autoimmune MRL-lpr/lpr mice: immuno-
pathogenesis, therapeutic approaches and relevance to similar
human diseases. Ann. Rheum. Dis. 52:S48–54 (Suppl.).
44. Haas, C., B. Ryffel, and M. Le Hir. 1997. IFN-g is essential
for the development of autoimmune glomerulonephritis in
MRL/lpr mice. J. Immunol. 158:5484–5491.
45. Alexander, E.L., C.F. Moyer, G.S. Travlos, J.B. Roths and
E.D. Murphy. 1985. Two histopathologic types of inflamma-
tory vascular disease in MRL/Mp autoimmune mice. Model
for human vasculitis in connective tissue disease. Arthritis
Rheum. 28:1146–1155.
46. Bullard, D.C., B.D. King, M.J. Hicks, B. Dupont, A.L.
Beaudet, and K.B. Elkon. 1997. Intercellular adhesion mole-
cule-1 deficiency protects MRL/MpJ-Faslpr mice from early
lethality. J. Immunol. 159:2058–2067.